Integra LifeSciences Holdings (IART) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.009x

Based on the latest financial reports, Integra LifeSciences Holdings (IART) has a cash flow conversion efficiency ratio of 0.009x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($9.80 Million) by net assets ($1.04 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IART equity to assets ratio to measure how much of total assets are equity-financed.

Integra LifeSciences Holdings - Cash Flow Conversion Efficiency Trend (1995–2025)

This chart illustrates how Integra LifeSciences Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Integra LifeSciences Holdings's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Integra LifeSciences Holdings Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Integra LifeSciences Holdings ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Yihai International Holding Ltd
F:YIR
0.024x
Xinxiang Richful Lube Additive Co. Ltd
SHE:300910
0.050x
Hunan Boyun New Materials Co Ltd
SHE:002297
0.037x
Dongguan Eontec Co Ltd
SHE:300328
-0.047x
Genting Plantations Bhd
KLSE:2291
0.031x
Saha Pathana Inter-Holding PCL
BK:SPI
-0.003x
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
0.008x
Wuhan East Lake High Technology Group Co Ltd
SHG:600133
-0.006x

Annual Cash Flow Conversion Efficiency for Integra LifeSciences Holdings (1995–2025)

The table below shows the annual cash flow conversion efficiency of Integra LifeSciences Holdings from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see Integra LifeSciences Holdings (IART) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $1.04 Billion $50.38 Million 0.048x -42.33%
2024-12-31 $1.55 Billion $129.38 Million 0.084x -5.01%
2023-12-31 $1.59 Billion $139.96 Million 0.088x -39.86%
2022-12-31 $1.80 Billion $264.47 Million 0.147x -20.96%
2021-12-31 $1.68 Billion $312.43 Million 0.185x +37.82%
2020-12-31 $1.51 Billion $203.83 Million 0.135x -17.63%
2019-12-31 $1.42 Billion $231.43 Million 0.163x +12.55%
2018-12-31 $1.38 Billion $199.68 Million 0.145x +21.93%
2017-12-31 $962.31 Million $114.54 Million 0.119x -14.14%
2016-12-31 $839.67 Million $116.41 Million 0.139x +10.26%
2015-12-31 $751.44 Million $94.48 Million 0.126x +11.45%
2014-12-31 $704.32 Million $79.46 Million 0.113x +41.94%
2013-12-31 $670.18 Million $53.27 Million 0.079x -29.91%
2012-12-31 $517.77 Million $58.72 Million 0.113x -46.45%
2011-12-31 $492.64 Million $104.33 Million 0.212x +0.29%
2010-12-31 $499.96 Million $105.57 Million 0.211x -34.41%
2009-12-31 $444.88 Million $143.24 Million 0.322x +55.33%
2008-12-31 $350.21 Million $72.59 Million 0.207x +14.79%
2007-12-31 $260.43 Million $47.03 Million 0.181x -25.42%
2006-12-31 $296.16 Million $71.70 Million 0.242x +23.43%
2005-12-31 $289.82 Million $56.85 Million 0.196x +54.92%
2004-12-31 $307.82 Million $38.98 Million 0.127x -2.37%
2003-12-31 $268.53 Million $34.83 Million 0.130x +0.39%
2002-12-31 $247.60 Million $31.98 Million 0.129x +67.89%
2001-12-31 $204.06 Million $15.70 Million 0.077x +183.43%
2000-12-31 $53.78 Million $-4.96 Million -0.092x -240.18%
1999-12-31 $38.00 Million $2.50 Million 0.066x +121.08%
1998-12-31 $31.40 Million $-9.80 Million -0.312x -41.43%
1997-12-31 $35.80 Million $-7.90 Million -0.221x -27.99%
1996-12-31 $46.40 Million $-8.00 Million -0.172x +46.43%
1995-12-31 $17.40 Million $-5.60 Million -0.322x --

About Integra LifeSciences Holdings

NASDAQ:IART USA Medical Devices
Market Cap
$1.30 Billion
Market Cap Rank
#7672 Global
#2290 in USA
Share Price
$16.65
Change (1 day)
-2.75%
52-Week Range
$8.90 - $19.85
All Time High
$76.63
About

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural … Read more